Clinical observation of oxaliplatin combined with S-1 on the patients with advanced breast cancer

doi:10.3760/cma.j.issn.1673-422X.2016.05.003

Abstract

Abstract: ObjectiveTo evaluate the efficacy and toxicity of the combination of oxaliplatin and S1 in the treatment of patients with advanced breast cancer. MethodsA total of 72 patients with advanced breast cancer after the treatment failuer of anthracycline and taxane were treated with oxaliplatin and S1. The first day, they were given oxaliplatin, 135 mg/m2, with the 5% glucose injection 500 ml, the time of intravenous drip should be more than 2 hours. And the S1 was taken after breakfast and dinner, the dose was 4060 mg, and the time of duration was 2 weeks, then they had 7 days to rest. The cycle was 21 days. Every 2 cycles, we estimated the efficacy. Patients who were effective and stable kept that chemotherapy regimens, the maximum duration was 6 cycles. The efficacy and toxicities were evaluated after cycles of chemotherapy. ResultsTwo cases (2.8%) had complete response (CR), 26 cases (36.1%) had partial response (PR). The response rate (RR) was 38.9% and the disease control rate (DCR) was 69.4%. The median progress free survival (PFS) was 7.7 months and the median overall survival (OS) was 12.3 months. Subgroup analysis showed that the OS of patients who belong to stage Ⅳ, had two or more metastases or with failure treatment after being treated with anthracycline and taxane was notably shorter than the patients who belong to stage ⅢC, only one metastasis, with effective treatment after being treated with anthracycline and taxane, and the differences were statistically significant (10.5 months vs. 15.0 months, χ2=4.469, P=0.035; 9.3 months vs. 15.0 months, χ2=8.297, P=0.004; 10.0 months vs. 14.0 months, χ2=4.077, P=0.043). The main side effects were neutropenia (19.4%), nausea (8.3%) and nerve toxicity (2.8%), mainly 34 degree, and could be welltolerated. The others were diarrhea, impaired liver function, stomatitis, anemia and handfoot syndrome, mainly 12 degree. ConclusionOxaliplatin combined with S1 is effective and tolerable in treatment of patients with advanced breast cancer, the adverse reactions can be tolerated.

Key words: Breast neoplasms, Neoplasms metastasis, Drug therapy

Liu Jun, Xiao Yang, Ma Yihui, Guo Jianxiong, Liu Yangchen, Huang Xiaohong, Zhang Rongxia. Clinical observation of oxaliplatin combined with S-1 on the patients with advanced breast cancer[J]. Journal of International Oncology, 2016, 43(5): 330-334.

References

［1］ Langlands F, White J, Kearins O, et al. Contralateral breast cancer: incidence according to ductal or lobular phenotype of the primary［J］. Clin Radiol, 2016, 71(2): 159-163. DOI: 10.1016/j.crad.2015.10.030. ［2］ Teng R, Hu Y, Zhou J, et al. Overexpression of Lin28 decreases the chemosensitivity of gastric cancer cells to oxaliplatin, paclitaxel, doxorubicin, and fluorouracil in part via microRNA107［J］. PLoS One, 2015, 10(12): e0143716. DOI: 10.1371/journal.pone.0143716. ［3］ Saek T, Takashima S, Sano M, et al. A phase Ⅱ study of S1 in patients with metastatic breast cancer—a Japanese trial by the S1 Cooperative Study Group, Breast Cancer Working Group［J］. Breast Cancer, 2004, 11(2): 194-202. ［4］ Schonberg MA, Li VW, Eliassen AH, et al. Performance of the breast cancer risk assessment Tool among women age 75 years and older［J］. J Natl Cancer Inst, 2016, 108: 3. DOI: 10.1093/jnci/djv348. ［5］ Brentnall AR, Harkness EF, Astley SM, et al. Mammographic density adds accuracy to both the TyrerCuzick and gail breast cancer risk models in a prospective UK screening cohort［J］. Breast Cancer Res, 2015, 17(1): 147-156. DOI: 10.1186/s1305801506535. ［6］ Schneck H, Gierke B, Uppenkamp F, et al. EpCAMIndependent enrichment of circulating tumor cells in metastatic breast cancer［J］. PLoS One, 2015, 10(12): e0144535. DOI: 10.1371/journal.pone.0144535. ［7］ Badwe R, Gupta S, Nair N, et al. Survival of patients with metastatic breast cancer with or without locoregional therapy—Authors′ reply［J］. Lancet Oncol, 2015, 16(16): e587-588. DOI: 10.1016/S14702045(15)004799. ［8］ Honda K, Gyawali B, Ando Y. Survival of patients with metastatic breast cancer with or without locoregional therapy［J］. Lancet Oncol, 2015, 16(16): e586. DOI: 10.1016/S14702045(15)00368X. ［9］ Weycker D, Li X, Edelsberg J, et al. Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens［J］. Support Care Cancer, 2014, 22(12): 3275-3285. DOI: 10.1007/s0052001423625. ［10］ HashemiMoghaddam H, KazemiBagsangani S, Jamili M, et al. Evaluation of magnetic nanoparticles coated by 5fluorouracil imprinted polymer for controlled drug delivery in mouse breast cancer model［J］. Int J Pharm, 2016, 497(1/2): 228-238. DOI: 10.1016/j.ijpharm.2015.11.040. ［11］ Lin Y, Lv F, Liu F, et al. High expression of pyruvate kinase M2 is associated with chemosensitivity to epirubicin and 5Fluorouracil in breast cancer［J］. J Cancer, 2015, 6(11): 1130-1139. DOI: 10.7150/jca.12719. ［12］ Kawazoe H, Shimasaki M, Ueno M, et al. Risk factors for discontinuation of s1 adjuvant chemotherapy for gastric cancer［J］. J Cancer, 2015, 6(5): 464-469. DOI: 10.7150/jca.11189. ［13］ Taira N, Aogi K, Ohsumi S, et al. S1 (TS1) maintained complete response for approximately 10 years in a case of metastatic breast cancer［J］. Breast Cancer, 2006, 13(2): 220-224. ［14］ Ito Y, Osaki Y, Tokudome N, et al. Efficacy of S1 in heavily pretreated patients with metastatic breast cancer: crossresistance to capecitabine［J］. Breast Cancer, 2009, 16(2): 126-131. DOI: 10.1007/s1228200800739. ［15］ Hara F, Kiyoto S, Takahashi M, et al. Efficacy and safety of S1 in patients with metastatic breast cancer［J］. Oncology, 2010, 79(3/4): 273-277. ［16］ Yamamoto K, Chiba N, Chiba T, et al. Transient receptor potential ankyrin 1 that is induced in dorsal root ganglion neurons contributes to acute cold hypersensitivity after oxaliplatin administration［J］. Mol Pain, 2015, 11(1): 69-79. DOI: 10.1186/s1299001500728. ［17］ Kolomeyevskaya NV, Lele SB, Miller A, et al. Oxaliplatin is a safe alternative option for patients with recurrent gynecologic cancers after hypersensitivity reaction to Carboplatin［J］. Int J Gynecol Cancer, 2015, 25(1): 42-48. DOI: 10.1097/IGC.0000000000000307.

[1]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[3]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[4]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[5]	Yue Hongyun, Zhang Baihong. Differentiation therapies in human cancers [J]. Journal of International Oncology, 2024, 51(2): 109-113.
[6]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[7]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[8]	Gu Huayan, Zhu Teng, Guo Guilong. Breast microbiota and breast cancer： present and future [J]. Journal of International Oncology, 2024, 51(1): 55-58.
[9]	Wang Jing, Xu Wenting. Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm [J]. Journal of International Oncology, 2023, 50(9): 520-526.
[10]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying. Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients [J]. Journal of International Oncology, 2023, 50(9): 527-531.
[11]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng. Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway [J]. Journal of International Oncology, 2023, 50(8): 449-456.
[12]	Pan Shulan, Liu Chang, He Ping. Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer [J]. Journal of International Oncology, 2023, 50(8): 457-462.
[13]	Li Chenxi, Zhao Hongwei. Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery [J]. Journal of International Oncology, 2023, 50(6): 342-347.
[14]	Wang Wende, Zeng De. Research progress on the mechanism of endocrine therapy resistance for breast cancer [J]. Journal of International Oncology, 2023, 50(6): 352-356.
[15]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.